Moreover, the use of the reversible 26S proteosome inhibitor bortezomib, which inhibits NF-κB activity, is an effective and approved agent in the treatment of multiple myeloma (Baud and Karin, 2009). The gene discussed is NFKB1; the disease is plasma cell myeloma.